This Week in Neurology: Neuroprotective Strategies and Metabolic Influences on Disease

This week’s research highlights various pharmacological and biological pathways that may influence neurological outcomes. In BMJ Open, a randomized controlled trial protocol describes a study involving 912 patients undergoing elective cardiac surgery with cardiopulmonary bypass ^[1].

The researchers are designing this protocol to explore how neuroprotective anesthesia targets might reduce silent brain infarction and perioperative neurocognitive disorders; however, as it is a protocol, no results regarding efficacy are currently available ^[1].

Moving toward the role of biomarkers in early detection, a study in Alzheimer's research & therapy describes an observational study of 330 cognitively unimpaired, Amyloid-beta positive older adults ^[2].

The authors found that a combined p-tau217 and tau-PET biomarker profile predicted the fastest cognitive decline (d = -1.84) and identified high-risk patients with hazard ratios up to 9.98, which may assist in more precise trial prioritization ^[2].

Research also explored the complexities of signaling pathways and metabolic influences on neurological health. In Frontiers in Medicine, a systematic review examines how Aryl hydrocarbon receptor (AhR) signaling exhibits dual neurotoxic or neuroprotective effects depending on specific ligand types in Alzheimer's and Parkinson's disease; specifically, gut-derived metabolites may offer potential neuroprotective effects ^[3].

A separate study in the same journal explores how DPP-4 inhibitors might mitigate drug-resistant epilepsy risk through a hypothesized gut microbiota-SCFA-GLP-1 signaling pathway ^[4].

Additionally, another narrative review in Frontiers in Medicine synthesizes evidence suggesting that diabetes mellitus acts as a context-dependent modifier of risk and phenotype across various neurological conditions ^[5].